The Challenge
At Month 5 of a critical anti-infective clinical trial — under the management of another CRO — only 16 patients had been recruited, far below the target of 43. The study, run across 17 U.S. sites, was struggling. Recruitment had stalled, and the existing CRO couldn’t overcome site-level and therapy-specific hurdles. Micron was brought in to turn it around.
Micron’s Contribution
When Micron took over, recruitment was stuck at under 5 patients/month, well short of the 8/month target. Within just one month, we hit the target. In the months that followed, we didn’t just meet expectations — we consistently exceeded them. By the final month, patient recruitment reached an impressive 140, closing the study on time. What made the difference? Our in-depth therapy area knowledge and renewed site engagement. By understanding each site’s strengths and blockers, our team helped remove recruitment barriers fast.
The Result
Prior to Micron’s involvement, recruitment was <5 patients/month, well below the target of 8 patients/month. Within the first month of Micron starting the study, monthly patient recruitment attained the target. Subsequent months saw recruitment rates above the monthly target rate. Consequently, the full complement of patient recruitment was achieved on schedule
Phase IIb/c trial of a novel anti-tuberculosis oral regimen completed within one year
Recruitment of patients with tuberculosis can be challenging, and retaining participation of the full quota of 122 patients to assess response to treatment was crucial to the trial’s success.
Rapid initiation and agile delivery of a complex Phase I COVID vaccine study
This successful trial was completed when the milestone of database lock was achieved just four weeks after last patient last visit.